SynthesisMedicine2026
Causal validation of immune antibody responses and nonalcoholic fatty liver disease: Evidence from Mendelian randomization and meta-analysis.
Synthesis in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, an increasing number of observational studies have reported the influence of immunity and antibodies on nonalcoholic fatty liver disease (NAFLD). However, no Mendelian randomization (MR) studies have yet been conducted to investigate the causal relationship in NAFLD. Based on a 2-sample MR framework, this study conducted MR analyses between 46 antibody immune response phenotypes and NAFLD using data from 2 different sources. Subsequently, the primary results from the inverse-variance weighted method were subjected to meta-analysis, and multiple testing correction was applied to the meta-analysis thresholds to ensure result accuracy. Finally, reverse MR analyses were performed to examine potential reverse causality between the antibody immune response phenotypes and NAFLD. MR analyses were conducted between 46 antibody immune response phenotypes and NAFLD using data from both the FinnGen R12 and the OpenGWAS databases. The inverse-variance weighted results from the 2 datasets were then combined through meta-analysis, and multiple testing correction was applied to the significance thresholds. The meta-analysis revealed an odds ratio of 1.06 (95% confidence interval: 1.02-1.11, P = .004). Moreover, the positive antibody immune response phenotype - Helicobacter pylori (H pylori) urease antibody levels - did not show evidence of reverse causality with NAFLD in either of the 2 datasets. The antibody immune response phenotype H pylori urease antibody levels is a risk factor for NAFLD, with the risk increase explicitly quantified as approximately 6% based on MR analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.